The stock of China Pharma Holdings Inc. (AMEX:CPHI) decreased by -$0.01 on Monday to finish at $0.21, down -8.04 percent. The last five days have seen an average of 2,036,380 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.7530. The average number of shares traded over the last 20 days was 1,837,795, while the average volume over the last 50 days totaled 825,600.
CPHI stock dropped -36.62% since last month. On 08/28/23, the company’s shares reached a one-month low of $0.1104. The stock touched a high of $2.46 on 01/12/23, after rallying from a low of $0.21 in 52 weeks. The price of CPHI stock has declined by -78.52% or -$0.7530 this year, reaching a new high 4 times. Still, the stock price is down -91.62% from the 52-week high.
Valuation Metrics
Beta for the stock is 0.54. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.30, the price-to-book (PB) ratio of 0.47.
Financial Health
For the three months ended September 29, China Pharma Holdings Inc.’s quick ratio was 0.20, while its current ratio was 0.50, indicating its inability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is -0.80% percent. China Pharma Holdings Inc.’s operating margin stood at -33.40% for the same period. Based on annual data, it had gross profit of -$0.49 million and revenue of $8.1 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CPHI’s return on assets (ROA) during the last 12 months has been -18.60%. There was a -33.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -77.40%.
Earnings Surprise
According to China Pharma Holdings Inc.’s quarterly financial report for the quarter that ended September 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.1 million, while revenues fell by -46.36% to $1.96 million. It was predicted that China Pharma Holdings Inc.’s quarterly earnings would be $0.8, but it ended up being $1.2, beating the consensus by -33.30%. EBITDA was $0.24 million for the quarter. At the end of China Pharma Holdings Inc.’s most recent quarter ended September 29, its liabilities totaled 11.35 million, while its total debt was $7.79 million. Equity owned by shareholders amounts to $11.43 million.
Technical Picture
Here’s a quick look at China Pharma Holdings Inc.’s (CPHI) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 33.29%, suggesting the stock is Neutral, with a 174.03% historical volatility rate.
The stochastic %K and %D were 20.73% and 22.87% respectively, while the average true range (ATR) was 0.0703. Based on the 14-day stochastic reading of 39.18%, the RSI (14) reading is 34.46%. On the 9-day MACD Oscillator, the stock is at -0.0180, and the 14-day reading is at -0.0208.
Analyst Ratings
In its analyst report released on January 08, 2010, Rodman & Renshaw began covering China Pharma Holdings Inc. (AMEX: CPHI). The stock was rated as a Mkt outperform by the brokerage firm. Analysts have assigned China Pharma Holdings Inc. (CPHI) an Buy rating. CPHI is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is CPHI’s price target for the next 12 months?
The current consensus forecast for the stock is between $45.00 and $45.00, with a median target price of $45.00. In analyzing these forecasts, the average price target given by analysts for China Pharma Holdings Inc. (CPHI) is $45.00.
